Argus Research analyst Jasper Hellweg upgrades $AbbVie (ABBV.US)$ to a buy rating.
According to TipRanks data, the analyst has a success rate of 56.8% and a total average return of 8.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:
AbbVie has reported another strong quarter, and attention is now shifting towards emraclidine and the outlook for the year 2025.
The firm has adjusted its outlook on AbbVie following the company's strong Q3 results and an increased revenue forecast for 2024. This positive shift is underpinned by an enhanced earnings projection for 2025. Despite this optimistic view, a balanced perspective is maintained when assessing the company's long-term growth prospects in relation to its present market valuation.
Following a robust third-quarter report characterized by surpassing expectations and upward revisions, optimism in the growth outlook is bolstered. This sentiment is further reinforced by increased projections, primarily driven by the performance of Rinvoq and Skyrizi, although tempered by moderated expectations for aesthetics and Humira sales.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
